-
Journal of the American College of... Oct 2020
Topics: Coronary Artery Bypass; Humans; Myocardial Infarction
PubMed: 33004128
DOI: 10.1016/j.jacc.2020.08.024 -
Catheterization and Cardiovascular... Dec 2021Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is associated with significant morbidity and mortality. (Review)
Review
BACKGROUND
Acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) is associated with significant morbidity and mortality.
METHODS
We provide an overview of previously conducted studies on the use of mechanical circulatory support (MCS) devices in the treatment of AMI-CS and difficulties which may be encountered in conducting such trials in the United States.
RESULTS
Well powered randomized control trials are difficult to conduct in a critically ill patient population due to physician preferences, perceived lack of equipoise and challenges obtaining informed consent.
CONCLUSIONS
With growth in utilization of MCS devices in patients with AMI-CS, efforts to perform well-powered, randomized control trials must be undertaken.
Topics: Heart-Assist Devices; Humans; Intra-Aortic Balloon Pumping; Myocardial Infarction; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Treatment Outcome; United States
PubMed: 33682260
DOI: 10.1002/ccd.29593 -
Journal of the American College of... Sep 2021
Topics: Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; ST Elevation Myocardial Infarction
PubMed: 34556315
DOI: 10.1016/j.jacc.2021.08.001 -
Annals of the Academy of Medicine,... Mar 2010Acute myocardial infarction (AMI) in pregnant women is a rare but potentially lethal occurrence that should be carefully managed, especially in consideration of cardiac... (Review)
Review
Acute myocardial infarction (AMI) in pregnant women is a rare but potentially lethal occurrence that should be carefully managed, especially in consideration of cardiac conditions being a rising cause of maternal deaths. Risk factors for AMI occurrence, in addition to typical cardiac-related risk factors, include medical conditions such as (pre) eclampsia, blood transfusions, thrombophilia and postpartum infections. Being older, multigravida or in the third trimester of pregnancy is also associated with an increased risk. The pathophysiological causes underlying AMI in pregnancy are diverse but generally associated with the coagulative and physiological changes related to the pregnancy. The selection of diagnostic modality and treatment options require careful consideration for pregnancy-related changes as well as risk of harm to the patient and fetus. This paper serves to review available literature regarding an extensive range of management issues that directly impact on maternal and fetal outcomes.
Topics: Adult; Female; Humans; Myocardial Infarction; Pregnancy; Pregnancy Complications, Cardiovascular; Young Adult
PubMed: 20372762
DOI: No ID Found -
Clinical Obstetrics and Gynecology Dec 2020Pregnancy-related maternal mortality and morbidity rates continue to increase in the United States despite global improvements in maternal outcomes. The unique...
Pregnancy-related maternal mortality and morbidity rates continue to increase in the United States despite global improvements in maternal outcomes. The unique hemodynamic and physiological changes of pregnancy results in a 3- to 4-fold increased risk of acute myocardial infarction (AMI) which causes a substantial proportion of all maternal cardiac deaths. In addition to atherosclerosis, pregnancy-associated AMI is commonly caused by nonatherosclerotic etiologies such as spontaneous coronary artery dissection, embolus to the coronary artery, and coronary vasospasm. Herein, the epidemiology, etiologies, presentation, diagnosis, and management of AMI in pregnancy is discussed along with future directions for multidisciplinary care.
Topics: Coronary Disease; Coronary Vessel Anomalies; Dissection; Female; Humans; Myocardial Infarction; Pregnancy; United States
PubMed: 32701519
DOI: 10.1097/GRF.0000000000000558 -
Scientific Reports Feb 2024The ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation Myocardial Infarction (NSTEMI) might occur because of coronary artery stenosis. The gene biomarkers...
The ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation Myocardial Infarction (NSTEMI) might occur because of coronary artery stenosis. The gene biomarkers apply to the clinical diagnosis and therapeutic decisions in Myocardial Infarction. The aim of this study was to introduce, enrich and estimate timely the blood gene profiles based on the high-throughput data for the molecular distinction of STEMI and NSTEMI. The text mining data (50 genes) annotated with DisGeNET data (144 genes) were merged with the GEO gene expression data (5 datasets) using R software. Then, the STEMI and NSTEMI networks were primarily created using the STRING server, and improved using the Cytoscape software. The high-score genes were enriched using the KEGG signaling pathways and Gene Ontology (GO). Furthermore, the genes were categorized to determine the NSTEMI and STEMI gene profiles. The time cut-off points were identified statistically by monitoring the gene profiles up to 30 days after Myocardial Infarction (MI). The gene heatmaps were clearly created for the STEMI (high-fold genes 69, low-fold genes 45) and NSTEMI (high-fold genes 68, low-fold genes 36). The STEMI and NSTEMI networks suggested the high-score gene profiles. Furthermore, the gene enrichment suggested the different biological conditions for STEMI and NSTEMI. The time cut-off points for the NSTEMI (4 genes) and STEMI (13 genes) gene profiles were established up to three days after Myocardial Infarction. The study showed the different pathophysiologic conditions for STEMI and NSTEMI. Furthermore, the high-score gene profiles are suggested to measure up to 3 days after MI to distinguish the STEMI and NSTEMI.
Topics: Humans; ST Elevation Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Prospective Studies; Myocardial Infarction; Gene Expression; Risk Factors
PubMed: 38341440
DOI: 10.1038/s41598-024-54086-w -
Journal of Cardiovascular Pharmacology... 2011Almost all published preclinical studies of cardioprotective agents include a measurement of area at risk, infarct size, and thus allow determination of myocardial... (Review)
Review
Almost all published preclinical studies of cardioprotective agents include a measurement of area at risk, infarct size, and thus allow determination of myocardial salvage as an indicator of therapeutic benefit. Until recently, single-photon emission tomography (SPECT) imaging with injection of sestamibi prior to intervention was the only clinical method suitable for making similar assessments in patients. Over the past 5 years, a large number of articles have documented that magnetic resonance imaging (MRI) can noninvasively determine area at risk, infarct size, and myocardial salvage. While T2-weighted imaging has been the method used most commonly, precontrast T1-weighted images and early gadolinium enhancement (EGE) images can also determine the size of the area at risk. All 3 of these MRI methods detect the area at risk based on myocardial edema resulting from ischemia. Late gadolinium enhancement (LGE) images provide a well-accepted reference standard for infarct size in all of those methods. Finally, LGE images can also provide a single modality measure of myocardial salvage based on the "wave front" of myocardial injury associated with the progressively more severe damage associated with acute myocardial infarction (MI). Essentially, the LGE images can provide an endocardial-based snap shot of infarct size and salvaged myocardium is estimated as the viable myocardium within the circumferential extent of the infarct. Thus, the purpose of this review is to provide an overview of how MRI can determine the area at risk, infarct size, and thus measure myocardial salvage.
Topics: Contrast Media; Gadolinium; Humans; Magnetic Resonance Imaging; Myocardial Infarction; Organotechnetium Compounds; Radionuclide Imaging
PubMed: 21821534
DOI: 10.1177/1074248411412378 -
British Journal of Anaesthesia Jul 2004
Review
Topics: Humans; Myocardial Infarction; Myocardial Ischemia; Postoperative Complications; Risk Factors
PubMed: 15096440
DOI: 10.1093/bja/aeh147 -
Journal of Cardiology Jul 2010The Korea Acute Myocardial Infarction Registry (KAMIR) was the first nationwide, population-based, multicenter data collection registry in Korea designed to track... (Review)
Review
The Korea Acute Myocardial Infarction Registry (KAMIR) was the first nationwide, population-based, multicenter data collection registry in Korea designed to track outcomes of patients presenting with acute myocardial infarction (AMI). The registry included 51 community and teaching hospitals and contained data on 14,870 patients through January 2008. Patients with non-ST-elevation myocardial infarction had a higher prevalence of co-morbidities and worse outcome than patients with ST-elevation myocardial infarction after being discharged from hospital, emphasizing the need for aggressive outpatient management of these patients. Risk factors and prognosis after AMI were similar to those in other registries from the West. A number of innovative approaches have been implemented in numerous studies generated by the KAMIR and have set standards of care for AMI in the Korean population.
Topics: Aged; Humans; Korea; Myocardial Infarction; Registries; Risk Factors
PubMed: 20554156
DOI: 10.1016/j.jjcc.2010.04.002 -
Heart (British Cardiac Society) Oct 2020
Topics: Humans; Limit of Detection; Myocardial Infarction; Patient Discharge; Troponin I
PubMed: 32747496
DOI: 10.1136/heartjnl-2020-317012